Trials / Completed
CompletedNCT06091956
A Study of Deucravacitinib to Treat LPP and FFA
Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | 6 milligram (mg) orally administrated, twice daily |
Timeline
- Start date
- 2023-11-07
- Primary completion
- 2024-05-21
- Completion
- 2024-12-24
- First posted
- 2023-10-23
- Last updated
- 2025-06-08
- Results posted
- 2025-06-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06091956. Inclusion in this directory is not an endorsement.